Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros SCHK HK-Global Quality Factor Index (ASHGQLT)
5/28/2026, 12:00:00 AM
Announced that CVS Caremark will restore preferred formulary coverage for its weight-loss drug Zepbound effective October 1, 2026, and add its oral drug Foundayo effective June 1, 2026, significantly expanding patient access. High importance is estimated due to the expected >10% price impact from increased market reach.
Korean Translation
CVS 케어마크가 체중 감량 치료제 제파운드에 대한 보험 등재를 2026년 10월 1일부터 복원하고, 경구용 치료제 파운다요를 2026년 6월 1일부터 추가할 것이라고 발표하여 환자 접근성이 크게 확대됨. 시장 점유율 확대에 따른 10% 이상의 주가 영향이 예상되어 중요도를 'High'로 설정함.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Lam Research Corp (LRCX) · Earnings Release
Q4 FY2026 earnings release scheduled for 2026-07-29. Estimated 1% price impact for the announcement.
7/29/2026, 12:00:00 AM
GE Vernova Inc (GEV) · Earnings Release
Q2 2026 earnings release is scheduled. This is estimated to have a low impact (~1%) as a routine announcement, scheduled.
7/22/2026, 12:00:00 AM
China Nonferrous Mining Corp Ltd (1258) · Other
Ex-dividend date for the final 2025 dividend of US$0.041446 per share on June 30, 2026, announced on March 26, 2026; Low importance is estimated due to typical minor price adjustments, scheduled.
6/30/2026, 12:00:00 AM
Lam Research Corp (LRCX) · Other
Quarterly dividend of $0.26 per share, ex-dividend date on 2026-06-17. The dividend was announced on May 21, 2026. Estimated 1% price impact as a routine corporate action.
6/17/2026, 12:00:00 AM
KLA Corp (KLAC) · Trading Issue
KLA Corp. will execute a ten-for-one forward stock split on June 12, 2026, with trading beginning on a split-adjusted basis scheduled. High importance is estimated due to the significant impact of stock splits on liquidity and retail accessibility.
6/12/2026, 12:00:00 AM